About Radionetics Oncology
Radionetics Oncology is a clinical-stage radiopharmaceutical company focused on the discovery and development of novel small molecule radiotherapeutics for a wide range of oncology indications. Its platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to cancers by binding selectively to G protein-coupled receptors (GPCRs) overexpressed on tumors. The company spun out of Crinetics Pharmaceuticals in 2021 and has entered into a strategic partnership with Eli Lilly.
Company details
Funding
Total raised
$82.5M
Last stage
Series A
Investors
Founders
R. Scott Struthers
Founder of Radionetics Oncology and founder/CEO of Crinetics Pharmaceuticals (Nasdaq: CRNX). Radionetics spun out of Crinetics, leveraging its nonpeptide drug discovery platform.
LinkedInAna Kusnetzow
Founding member of Radionetics and co-founder of Crinetics Pharmaceuticals. Co-led the Crinetics discovery program that gave rise to the nonpeptide targeted radiotherapeutics platform underlying Radionetics.
Brett Ewald
Founding member of Radionetics with 20 years of oncology experience. Previously SVP of Development and Corporate Strategy at DNAtrix and held leadership roles at Novartis Oncology.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.